BMO Capital analyst Evan Seigerman assigned a Buy rating to Pfizer (PFE – Research Report) yesterday and set a price target of $53.00. The company’s shares closed yesterday at $44.16.
Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Mirati Therapeutics. According to TipRanks, Seigerman has an average return of 6.5% and a 51.47% success rate on recommended stocks.
In addition to BMO Capital, Pfizer also received a Buy from Credit Suisse’s Trung Huynh in a report issued yesterday. However, on the same day, Barclays maintained a Hold rating on Pfizer (NYSE: PFE).
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $54.46 and a one-year low of $40.72. Currently, Pfizer has an average volume of 21.88M.
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PFE in relation to earlier this year. Most recently, in December 2022, Douglas Lankler, the EVP of PFE bought 191,862.00 shares for a total of $5,139,071.42.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Pfizer Inc Reported Earnings. Did it Beat Estimates?
- Pfizer Issues Weak 2023 Guidance; Expects Significant Sales Drop
- Pfizer CFO says increasing investments behind launch products and pipeline
- Pfizer expects revenue from COVID-19 products to grow in 2024
- Pfizer says FY23 guidance does not anticipate any share repurchases